Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma

Partyka, Susan; Dumas, Pamela; Ajani, Jaffer A.

doi:10.1002/(sici)1097-0142(19990601)85:11<2336::aid-cncr6>3.0.co;2-i

Cited by 8 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the investigators, this protocol was well tolerated, even in elderly patients. The median survival was 11 months, which was also confirmed by other investigators [66][67][68]. Raderer et al [68].…”

Section: Combination Chemotherapysupporting

confidence: 81%

See 1 more Smart Citation

Palliative chemotherapy for advanced gastric cancer

Wöhrer¹,

Raderer

Hejna³

2004

Annals of Oncology

158

117

View full text Add to dashboard Cite

Analysis of results shows chemotherapy to be superior to best supportive care alone. Combination chemotherapy compared with monochemotherapy is associated with significantly higher overall (complete plus partial) response rates but nevertheless results in similar survival. ECF (epirubicin, cisplatin and 5-fluorouracil) currently represents one of the most effective regimens for advanced gastric cancer, whereas among the newer combinations, irinotecan- or taxane-based regimens have also given promising results. In patients with a poor performance status, consideration could be given to leucovorin-modulated 5-fluorouracil alone. Prognosis for the majority of patients, however, remains poor, as increases in survival were moderate at best.

show abstract

Section: Combination Chemotherapysupporting

confidence: 81%

“…The median survival was 11 months, which was also confirmed by other investigators [66][67][68]. Raderer et al [68]. investigated the clinical effectiveness and tolerance of an oral modification of the ELF regimen in patients with advanced gastric cancer.…”

Section: Combination Chemotherapysupporting

confidence: 55%

Palliative chemotherapy for advanced gastric cancer

Wöhrer¹,

Raderer

Hejna³

2004

Annals of Oncology

158

117

View full text Add to dashboard Cite

show abstract

“…However, another study revealed a different clinical outcome [14]. Chemotherapy combined with GM-CSF for locoregional and metastatic gastric adenocarcinoma did not yield positive results in terms of improved treatment efficacy and prolonged survival in patients.…”

Section: Discussionmentioning

confidence: 98%

Granulocyte-Macrophage Colony-Stimulating Factor in Combination With Chemoradiation for Recurrent or Metastatic Cervical Cancer

Zhang,

Guo

2024

Cureus

View full text Add to dashboard Cite

Recurrent or metastatic cervical cancer carries a bleak prognosis and presents a formidable challenge in terms of treatment. Granulocyte-macrophage colony-stimulating factor (GM-CSF) increases the body's immune response by enhancing antigen presentation, which has been rarely reported in recurrent or metastatic cervical cancer. A 44-year-old woman presented to the hospital with vaginal bleeding four years after radical hysterectomy for stage IB2 squamous cell carcinoma (SCC) of the cervix (grade II-III). Gynecological examination and imaging revealed a vaginal mass, and the biopsy confirmed the recurrence of grade III SCC. The patient was treated with chemoradiation (CRT) combined with immunoadjuvant GM-CSF and achieved complete remission and a progression-free survival of two years.

show abstract

“…In a phase II trial by di Bartolomeo et al [25], 32% of patients had PRs, with a median survival of 10 months. Partyka et al [26], from the University of Texas M.D. Anderson Medical Center in Houston, reported a 14% response rate with ELF and a median survival of 7.8 months.…”

Section: Etoposide Leucovorin and 5-fluorouracilmentioning

confidence: 99%

Status of treatment for advanced gastric carcinoma

Tsai¹,

Safran²

2003

Curr Oncol Rep

View full text Add to dashboard Cite

Gastric cancer is the second most common cause of cancer death worldwide. Advanced gastric cancer is incurable. The most widely investigated single-agent chemotherapy is 5-fluorouracil (5-FU), with partial response rates up to 20%. Pilot phase II studies investigating combinations of 5-FU, anthracyclines, mitomycin, methotrexate, and platinums achieved higher response rates; however, the response rates declined in subsequent larger trials. Furthermore, toxicity was substantially higher in confirmatory trials, emphasizing the need to develop well-tolerated regimens prior to multi-institutional testing. Although phase III studies of combination regimens have not achieved a clear worldwide standard, the regimen of epirubicin, cisplatin, and continuous-infusion 5-FU achieved a survival benefit, possibly through the increased activity of infusional 5-FU combined with cisplatin. The taxanes, irinotecan and oxaliplatin, have recently shown important activity in gastric cancer. Patient accrual to a phase III trial comparing a docetaxel-based combination regimen with the regimen of cisplatin and 5-FU has completed accrual. Whether patients with adenocarcinomas of the proximal stomach and gastroesophageal junction will have the same response rates to these new agents as did patients with classical body and distal gastric cancers is unknown. It is anticipated that the development of these active new agents will ultimately improve survival for patients with advanced gastric cancer.

show abstract

Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma

Cited by 8 publications

References 18 publications

Palliative chemotherapy for advanced gastric cancer

Palliative chemotherapy for advanced gastric cancer

Granulocyte-Macrophage Colony-Stimulating Factor in Combination With Chemoradiation for Recurrent or Metastatic Cervical Cancer

Status of treatment for advanced gastric carcinoma

Contact Info

Product

Resources

About